Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Common Equity: 2009-2024

Historic Common Equity for Madrigal Pharmaceuticals (MDGL) over the last 12 years, with Dec 2024 value amounting to $754.4 million.

  • Madrigal Pharmaceuticals' Common Equity fell 19.48% to $625.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $625.7 million, marking a year-over-year decrease of 19.48%. This contributed to the annual value of $754.4 million for FY2024, which is 86.11% up from last year.
  • Madrigal Pharmaceuticals' Common Equity amounted to $754.4 million in FY2024, which was up 86.11% from $405.3 million recorded in FY2023.
  • Over the past 5 years, Madrigal Pharmaceuticals' Common Equity peaked at $754.4 million during FY2024, and registered a low of $196.1 million during FY2021.
  • In the last 3 years, Madrigal Pharmaceuticals' Common Equity had a median value of $405.3 million in 2023 and averaged $452.4 million.
  • Its Common Equity has fluctuated over the past 5 years, first plummeted by 42.39% in 2020, then spiked by 105.35% in 2023.
  • Over the past 5 years, Madrigal Pharmaceuticals' Common Equity (Yearly) stood at $240.0 million in 2020, then declined by 18.28% to $196.1 million in 2021, then rose by 0.65% to $197.4 million in 2022, then surged by 105.35% to $405.3 million in 2023, then spiked by 86.11% to $754.4 million in 2024.